The Central Board of Secondary Education has announced the exam form submission for Classes 10 and 12. Students appearing as private, repeat, compartment, or improvement candidates can register. The ...

Obesity has outpaced undernourishment to become the leading form of malnutrition worldwide for the first time among children and teenagers, according to UNICEF. The United Nations children’s agency ...

From September 9, 2025, the Central Board of Secondary Education will open a window for registrations for students who intend to appear in the 2025–26 Class 10 and 12 board exams as private candidates ...

As per CBSE's notification, only a particular group of students can apply as private candidates. They are: -2024–25 batch students who announced 'Essential Repeat' in the 2025 result. Mumbai News: ...

Sony released the Xperia 10 VI mid-ranger last June, so its successor is way overdue at this point. The good news is that we've already heard that the Xperia 10 VII is on its way, with a pretty ...

We know that nothing hits the spot quite like a homemade cookie. At the same time, we also know that a deep-rooted craving for a sweet treat doesn't always coincide with feeling productive enough to ...

THE APPLE Store has gone down, ahead of a highly anticipated announcement by the tech company. Fans think this suggests that Apple is finally going to unveil the iPhone 17 following similar “glitches” ...

Sony officially unveiled the Xperia 10 VII, its latest mid-range smartphone. It comes with a redesigned rear camera module and a number of improvements compared to its predecessor. The Sony Xperia 10 ...

The 2025 NFL season is upon us and Week 1 is teeming with fantasy implications for the remainder of the year. These are the 10 things I think you need to know before Week 2 kicks off. Two rookie tight ...

There’s more bad news for Tesla rival Lucid Motors. On Tuesday, shares of the luxury electric vehicle company Lucid Group (Nasdaq: LCID) fell a whopping 10% as the EV maker began trading following its ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

Sanofi's shares dropped over 10% due to concerns about Amlitelimab's Phase III trial results and future pipeline prospects. Amlitelimab met primary endpoints in atopic dermatitis treatment but showed ...